Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.




) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.1%. By the end of trading, Gilead rose $2.25 (3.0%) to $78.49 on average volume. Throughout the day, 19,460,872 shares of Gilead exchanged hands as compared to its average daily volume of 17,200,900 shares. The stock ranged in a price between $75.49-$78.67 after having opened the day at $76.15 as compared to the previous trading day's close of $76.24. Other companies within the Drugs industry that increased today were:

AVANIR Pharmaceuticals



), up 45.6%,

Adamas Pharmaceuticals



), up 15.3%,

22nd Century Group



), up 14.0% and

Supernus Pharmaceuticals



), up 8.4%.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $113.9 billion and is part of the health care sector. The company has a P/E ratio of 43.0, above the S&P 500 P/E ratio of 17.7. Shares are down 1.4% year to date as of the close of trading on Tuesday. Currently there are 18 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates


as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front,

Synthetic Biologics



), down 30.9%,

Auxilium Pharmaceuticals



), down 17.7%,




), down 15.8% and

Usana Health



), down 15.7% , were all laggards within the drugs industry with

Biogen Idec



) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.